Mitotic Slippage: an Old Tale with a New Twist

Overview

Journal Cell Cycle

Specialty Cell Biology

Date 2019 Jan 3

PMID 30601084

Citations 64

Authors

Debottam Sinha

Pascal H G Duijf

Kum Kum Khanna

Affiliations

Soon will be listed here.

Abstract

Targeting the mitotic machinery using anti-mitotic drugs for elimination of cancer cells is a century-old concept, which continues to be routinely used as a first line of treatment in the clinic. However, patient response remains unpredictable and drug resistance limits effectiveness of these drugs. Cancer cells exit from drug-induced mitotic arrest (mitotic slippage) to avoid subsequent cell death which is thought to be a major mechanism contributing to this resistance. The tumor cells that acquire resistance to anti-mitotic drugs have chromosomal instability (CIN) and are often aneuploid. In this review, we outline the key mechanisms involved in dictating the cell fate during perturbed mitosis and how these processes impede the efficacy of anti-mitotic therapies. Further, we emphasize the recent work from our laboratory, which highlights the functional role of CEP55 in protecting aneuploid cells from death. We also discuss the rationale of targeting CEP55 in vivo, which could prove to be a novel and effective therapeutic strategy for sensitizing cells to microtubule inhibitors and might offer significantly improved patient outcome. Abbreviations: APC/C: Anaphase-Promoting Complex/Cyclosome; BAD: BCL2-Associated agonist of cell Death; BAK1: BCL2 Antagonist Kinase1; BAX: BCL2-Associated X; BCL2: B-cell Chronic Lymphocytic Leukaemia (CLL)/Lymphoma 2; BH: BCL2 Homology Domain; BID: BH3-Interacting domain Death agonist; BIM: BCL2-Interacting Mediator of cell death; BUB: Budding Uninhibited by Benzimidazoles; CDC: Cell Division Cycle; CDH1: Cadherin-1; CDK1: Cyclin-Dependent Kinase 1; CEP55: Centrosomal Protein (55 KDa): CIN: Chromosomal Instability; CTA: Cancer Testis Antigen; EGR1: Early Growth Response protein 1; ERK: Extracellular Signal-Regulated Kinase; ESCRT: Endosomal Sorting Complexes Required for Transport; GIN: Genomic Instability; MAD2: Mitotic Arrest Deficient 2; MCL1: Myeloid Cell Leukemia sequence 1; MPS1: Monopolar Spindle 1 Kinase; MYT1: MYelin Transcription factor 1; PLK1: Polo Like Kinase 1; PUMA: p53-Upregulated Mediator of Apoptosis; SAC: Spindle Assembly Checkpoint; TAA: Tumor-Associated Antigen.

Citing Articles

Targeting Kinesins for Therapeutic Exploitation of Chromosomal Instability in Lung Cancer.

Zhang C, Wu B, Thu K Cancers (Basel). 2025; 17(4).

PMID: 40002279 PMC: 11853690. DOI: 10.3390/cancers17040685.

Onvansertib and Navitoclax Combination as a New Therapeutic Option for Mucinous Ovarian Carcinoma.

Petrella S, Colombo M, Marabese M, Grasselli C, Panfili A, Chiappa M Int J Mol Sci. 2025; 26(2).

PMID: 39859203 PMC: 11765470. DOI: 10.3390/ijms26020472.

High CDC20 levels increase sensitivity of cancer cells to MPS1 inhibitors.

Zheng S, Raz L, Zhou L, Cohen-Sharir Y, Tian R, Ippolito M EMBO Rep. 2025; 26(4):1036-1061.

PMID: 39838194 PMC: 11850905. DOI: 10.1038/s44319-024-00363-8.

DeSUMOylating isopeptidase 1 participates in the faithful chromosome segregation and vincristine sensitivity.

Ikeda Y, Yuki R, Saito Y, Nakayama Y FASEB J. 2024; 38(24):e70261.

PMID: 39698932 PMC: 11656513. DOI: 10.1096/fj.202401560RR.

Arrest and Attack: Microtubule-Targeting Agents and Oncolytic Viruses Employ Complementary Mechanisms to Enhance Anti-Tumor Therapy Efficacy.

De S, Ehrlich M Genes (Basel). 2024; 15(9).

PMID: 39336785 PMC: 11431212. DOI: 10.3390/genes15091193.

References

Shi J, Zhou Y, Huang H, Mitchison T . Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL. Cancer Res. 2011; 71(13):4518-26. PMC: 3129452. DOI: 10.1158/0008-5472.CAN-10-4336. View

Schvartzman J, Sotillo R, Benezra R . Mitotic chromosomal instability and cancer: mouse modelling of the human disease. Nat Rev Cancer. 2010; 10(2):102-15. PMC: 5526619. DOI: 10.1038/nrc2781. View

Harvey S, Charlet A, Haas W, Gygi S, Kellogg D . Cdk1-dependent regulation of the mitotic inhibitor Wee1. Cell. 2005; 122(3):407-20. DOI: 10.1016/j.cell.2005.05.029. View

Bennett A, Sloss O, Topham C, Nelson L, Tighe A, Taylor S . Inhibition of Bcl-xL sensitizes cells to mitotic blockers, but not mitotic drivers. Open Biol. 2016; 6(8). PMC: 5008013. DOI: 10.1098/rsob.160134. View

Edgar B, Zielke N, Gutierrez C . Endocycles: a recurrent evolutionary innovation for post-mitotic cell growth. Nat Rev Mol Cell Biol. 2014; 15(3):197-210. DOI: 10.1038/nrm3756. View

Upreti M, Chu R, Galitovskaya E, Smart S, Chambers T . Key role for Bak activation and Bak-Bax interaction in the apoptotic response to vinblastine. Mol Cancer Ther. 2008; 7(7):2224-32. PMC: 3276366. DOI: 10.1158/1535-7163.MCT-07-2299. View

Li M, Gao J, Li D, Yin Y . CEP55 Promotes Cell Motility via JAK2⁻STAT3⁻MMPs Cascade in Hepatocellular Carcinoma. Cells. 2018; 7(8). PMC: 6115913. DOI: 10.3390/cells7080099. View

Czabotar P, Lessene G, Strasser A, Adams J . Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2013; 15(1):49-63. DOI: 10.1038/nrm3722. View

Jia Y, Xiao Z, GongSun X, Xin Z, Shang B, Chen G . CEP55 promotes the proliferation, migration and invasion of esophageal squamous cell carcinoma via the PI3K/Akt pathway. Onco Targets Ther. 2018; 11:4221-4232. PMC: 6055835. DOI: 10.2147/OTT.S168861. View

10.

Harley M, Allan L, Sanderson H, Clarke P . Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest. EMBO J. 2010; 29(14):2407-20. PMC: 2910263. DOI: 10.1038/emboj.2010.112. View

11.

Perez de Castro I, de Carcer G, Malumbres M . A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy. Carcinogenesis. 2007; 28(5):899-912. DOI: 10.1093/carcin/bgm019. View

12.

Topham C, Taylor S . Mitosis and apoptosis: how is the balance set?. Curr Opin Cell Biol. 2013; 25(6):780-5. DOI: 10.1016/j.ceb.2013.07.003. View

13.

Topham C, Tighe A, Ly P, Bennett A, Sloss O, Nelson L . MYC Is a Major Determinant of Mitotic Cell Fate. Cancer Cell. 2015; 28(1):129-40. PMC: 4518499. DOI: 10.1016/j.ccell.2015.06.001. View

14.

Metzger-Filho O, Sun Z, Viale G, Price K, Crivellari D, Snyder R . Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. J Clin Oncol. 2013; 31(25):3083-90. PMC: 3753700. DOI: 10.1200/JCO.2012.46.1574. View

15.

Kalimutho M, Sinha D, Jeffery J, Nones K, Srihari S, Fernando W . CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer. EMBO Mol Med. 2018; 10(9). PMC: 6127888. DOI: 10.15252/emmm.201708566. View

16.

Zhang W, Mao J, Zhu W, Jain A, Liu K, Brown J . Centromere and kinetochore gene misexpression predicts cancer patient survival and response to radiotherapy and chemotherapy. Nat Commun. 2016; 7:12619. PMC: 5013662. DOI: 10.1038/ncomms12619. View

17.

Kumagai A, Dunphy W . The cdc25 protein controls tyrosine dephosphorylation of the cdc2 protein in a cell-free system. Cell. 1991; 64(5):903-14. DOI: 10.1016/0092-8674(91)90315-p. View

18.

Sinha D, Kalimutho M, Bowles J, Chan A, Merriner D, Bain A . Cep55 overexpression causes male-specific sterility in mice by suppressing Foxo1 nuclear retention through sustained activation of PI3K/Akt signaling. FASEB J. 2018; 32(9):4984-4999. DOI: 10.1096/fj.201701096RR. View

19.

Evans T, Rosenthal E, Youngblom J, Distel D, Hunt T . Cyclin: a protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division. Cell. 1983; 33(2):389-96. DOI: 10.1016/0092-8674(83)90420-8. View

20.

Duesberg P, Stindl R, Hehlmann R . Origin of multidrug resistance in cells with and without multidrug resistance genes: chromosome reassortments catalyzed by aneuploidy. Proc Natl Acad Sci U S A. 2001; 98(20):11283-8. PMC: 58721. DOI: 10.1073/pnas.201398998. View